Loading…

Construction and validation of a necroptosis-related prognostic signature in acute myeloid leukemia

Acute myeloid leukemia (AML), an uncommonly low 5-year survival and high mortality rate, is a potentially catastrophic diagnosed subtype of leukemia. The development of new prognostic markers is urgently needed to guide its treatment. Necroptosis is a newly defined biological process for regulating...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2024-05, Vol.103 (22), p.e38432
Main Authors: Pan, Yu-Qing, Yang, Kai, Zhang, Xi, Li, Yi-Xun, Guo, Chong, Chen, Zheng-Hui, Du, Yan
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c230t-1a6cdabb44f81c0fbe94e1b269379bd410a1d22d344548bba317045fb810a1013
container_end_page
container_issue 22
container_start_page e38432
container_title Medicine (Baltimore)
container_volume 103
creator Pan, Yu-Qing
Yang, Kai
Zhang, Xi
Li, Yi-Xun
Guo, Chong
Chen, Zheng-Hui
Du, Yan
description Acute myeloid leukemia (AML), an uncommonly low 5-year survival and high mortality rate, is a potentially catastrophic diagnosed subtype of leukemia. The development of new prognostic markers is urgently needed to guide its treatment. Necroptosis is a newly defined biological process for regulating cell death, and previous studies have confirmed that the abnormality of the physical function can lead to multiple malignancies. Here, we performed necroptosis-related genes (NRGs) to build a predictive model in the Cancer Genome Atlas (TCGA)-AML patients, thus exploring the correlation between the NRG prognosis signature (NRG score) of this model and immune infiltration, pathway activity, clinical features, and immunotherapy. Besides, we computed the statistical measure Spearman rank correlation between the NRG score and the Log IC50 values of therapeutic agents. Subsequently, we divided the TCGA-AML cohort into 2 groups, one with high scores and the other with low scores depending on the model score. AML patients with high NRG scores exhibited a lower estimated overall survival (OS) rate than those with low NRG scores, which was confirmed in the validation set. The prognostic value of the constructed NRG signature to the AML, independent of other variables, was demonstrated by uni- and multivariate stepwise regression analysis. When comparing the infiltrating states of specialized cells associated with immune system from the 2 groups, B cells naive, Plasma cells, and monocytes represented significant differences among various subgroups of samples. Moreover, the 30 hallmark-related pathways related to necroptosis characteristics were remarkably different between the high/low NRG score groups. And patients showed remarkable NRG score distribution in clinical features of bone marrow lymphocyte, category, and FAB classifications. Besides, we found that the BIRB0796, VX680, Vorinostat, and Axitinib positively related with NRG score, whereas CI. 1040, PD. 0325901, Z.L LNle. CHO, and AZD6244 negatively correlated with the NRG score. These drugs may provide a reference for subsequent treatment.
doi_str_mv 10.1097/MD.0000000000038432
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3102881499</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3102881499</sourcerecordid><originalsourceid>FETCH-LOGICAL-c230t-1a6cdabb44f81c0fbe94e1b269379bd410a1d22d344548bba317045fb810a1013</originalsourceid><addsrcrecordid>eNpdUMlOwzAQtRAISuELkJCPXFK8ZfERtWxSKy5wjrxMKkMSF9tB6t-TUhaJuYxG8968eQ-hC0pmlMjyerWYkb_ileDsAE1ozossl4U4RBNCWJ6VshQn6DTGV0IoL5k4RidcslySgk6Qmfs-pjCY5HyPVW_xh2qdVV-jb7DCPZjgN8lHF7MArUpg8Sb4de9jcgZHt-5VGgJgN_LNkAB3W2i9s7iF4Q06p87QUaPaCOfffYpe7m6f5w_Z8un-cX6zzAzjJGVUFcYqrYVoKmpIo0EKoJoVkpdSW0GJopYxy4XIRaW14rQkIm90tduM3qboan93fO99gJjqzkUDbat68EOsOSWsqqiQcoTyPXT0FmOApt4E16mwrSmpd-nWq0X9P92RdfktMOgO7C_nJ07-CZ13dlY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3102881499</pqid></control><display><type>article</type><title>Construction and validation of a necroptosis-related prognostic signature in acute myeloid leukemia</title><source>LWW Online</source><source>IngentaConnect Journals</source><source>PubMed Central</source><creator>Pan, Yu-Qing ; Yang, Kai ; Zhang, Xi ; Li, Yi-Xun ; Guo, Chong ; Chen, Zheng-Hui ; Du, Yan</creator><creatorcontrib>Pan, Yu-Qing ; Yang, Kai ; Zhang, Xi ; Li, Yi-Xun ; Guo, Chong ; Chen, Zheng-Hui ; Du, Yan</creatorcontrib><description>Acute myeloid leukemia (AML), an uncommonly low 5-year survival and high mortality rate, is a potentially catastrophic diagnosed subtype of leukemia. The development of new prognostic markers is urgently needed to guide its treatment. Necroptosis is a newly defined biological process for regulating cell death, and previous studies have confirmed that the abnormality of the physical function can lead to multiple malignancies. Here, we performed necroptosis-related genes (NRGs) to build a predictive model in the Cancer Genome Atlas (TCGA)-AML patients, thus exploring the correlation between the NRG prognosis signature (NRG score) of this model and immune infiltration, pathway activity, clinical features, and immunotherapy. Besides, we computed the statistical measure Spearman rank correlation between the NRG score and the Log IC50 values of therapeutic agents. Subsequently, we divided the TCGA-AML cohort into 2 groups, one with high scores and the other with low scores depending on the model score. AML patients with high NRG scores exhibited a lower estimated overall survival (OS) rate than those with low NRG scores, which was confirmed in the validation set. The prognostic value of the constructed NRG signature to the AML, independent of other variables, was demonstrated by uni- and multivariate stepwise regression analysis. When comparing the infiltrating states of specialized cells associated with immune system from the 2 groups, B cells naive, Plasma cells, and monocytes represented significant differences among various subgroups of samples. Moreover, the 30 hallmark-related pathways related to necroptosis characteristics were remarkably different between the high/low NRG score groups. And patients showed remarkable NRG score distribution in clinical features of bone marrow lymphocyte, category, and FAB classifications. Besides, we found that the BIRB0796, VX680, Vorinostat, and Axitinib positively related with NRG score, whereas CI. 1040, PD. 0325901, Z.L LNle. CHO, and AZD6244 negatively correlated with the NRG score. These drugs may provide a reference for subsequent treatment.</description><identifier>ISSN: 0025-7974</identifier><identifier>ISSN: 1536-5964</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000038432</identifier><identifier>PMID: 39259061</identifier><language>eng</language><publisher>United States</publisher><subject>Adult ; Aged ; Biomarkers, Tumor - genetics ; Female ; Humans ; Leukemia, Myeloid, Acute - drug therapy ; Leukemia, Myeloid, Acute - genetics ; Leukemia, Myeloid, Acute - mortality ; Leukemia, Myeloid, Acute - pathology ; Male ; Middle Aged ; Necroptosis - genetics ; Prognosis</subject><ispartof>Medicine (Baltimore), 2024-05, Vol.103 (22), p.e38432</ispartof><rights>Copyright © 2024 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c230t-1a6cdabb44f81c0fbe94e1b269379bd410a1d22d344548bba317045fb810a1013</cites><orcidid>0009-0009-6940-631 ; 0009-0009-6940-631X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39259061$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pan, Yu-Qing</creatorcontrib><creatorcontrib>Yang, Kai</creatorcontrib><creatorcontrib>Zhang, Xi</creatorcontrib><creatorcontrib>Li, Yi-Xun</creatorcontrib><creatorcontrib>Guo, Chong</creatorcontrib><creatorcontrib>Chen, Zheng-Hui</creatorcontrib><creatorcontrib>Du, Yan</creatorcontrib><title>Construction and validation of a necroptosis-related prognostic signature in acute myeloid leukemia</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Acute myeloid leukemia (AML), an uncommonly low 5-year survival and high mortality rate, is a potentially catastrophic diagnosed subtype of leukemia. The development of new prognostic markers is urgently needed to guide its treatment. Necroptosis is a newly defined biological process for regulating cell death, and previous studies have confirmed that the abnormality of the physical function can lead to multiple malignancies. Here, we performed necroptosis-related genes (NRGs) to build a predictive model in the Cancer Genome Atlas (TCGA)-AML patients, thus exploring the correlation between the NRG prognosis signature (NRG score) of this model and immune infiltration, pathway activity, clinical features, and immunotherapy. Besides, we computed the statistical measure Spearman rank correlation between the NRG score and the Log IC50 values of therapeutic agents. Subsequently, we divided the TCGA-AML cohort into 2 groups, one with high scores and the other with low scores depending on the model score. AML patients with high NRG scores exhibited a lower estimated overall survival (OS) rate than those with low NRG scores, which was confirmed in the validation set. The prognostic value of the constructed NRG signature to the AML, independent of other variables, was demonstrated by uni- and multivariate stepwise regression analysis. When comparing the infiltrating states of specialized cells associated with immune system from the 2 groups, B cells naive, Plasma cells, and monocytes represented significant differences among various subgroups of samples. Moreover, the 30 hallmark-related pathways related to necroptosis characteristics were remarkably different between the high/low NRG score groups. And patients showed remarkable NRG score distribution in clinical features of bone marrow lymphocyte, category, and FAB classifications. Besides, we found that the BIRB0796, VX680, Vorinostat, and Axitinib positively related with NRG score, whereas CI. 1040, PD. 0325901, Z.L LNle. CHO, and AZD6244 negatively correlated with the NRG score. These drugs may provide a reference for subsequent treatment.</description><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Female</subject><subject>Humans</subject><subject>Leukemia, Myeloid, Acute - drug therapy</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Leukemia, Myeloid, Acute - mortality</subject><subject>Leukemia, Myeloid, Acute - pathology</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Necroptosis - genetics</subject><subject>Prognosis</subject><issn>0025-7974</issn><issn>1536-5964</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpdUMlOwzAQtRAISuELkJCPXFK8ZfERtWxSKy5wjrxMKkMSF9tB6t-TUhaJuYxG8968eQ-hC0pmlMjyerWYkb_ileDsAE1ozossl4U4RBNCWJ6VshQn6DTGV0IoL5k4RidcslySgk6Qmfs-pjCY5HyPVW_xh2qdVV-jb7DCPZjgN8lHF7MArUpg8Sb4de9jcgZHt-5VGgJgN_LNkAB3W2i9s7iF4Q06p87QUaPaCOfffYpe7m6f5w_Z8un-cX6zzAzjJGVUFcYqrYVoKmpIo0EKoJoVkpdSW0GJopYxy4XIRaW14rQkIm90tduM3qboan93fO99gJjqzkUDbat68EOsOSWsqqiQcoTyPXT0FmOApt4E16mwrSmpd-nWq0X9P92RdfktMOgO7C_nJ07-CZ13dlY</recordid><startdate>20240531</startdate><enddate>20240531</enddate><creator>Pan, Yu-Qing</creator><creator>Yang, Kai</creator><creator>Zhang, Xi</creator><creator>Li, Yi-Xun</creator><creator>Guo, Chong</creator><creator>Chen, Zheng-Hui</creator><creator>Du, Yan</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0009-6940-631</orcidid><orcidid>https://orcid.org/0009-0009-6940-631X</orcidid></search><sort><creationdate>20240531</creationdate><title>Construction and validation of a necroptosis-related prognostic signature in acute myeloid leukemia</title><author>Pan, Yu-Qing ; Yang, Kai ; Zhang, Xi ; Li, Yi-Xun ; Guo, Chong ; Chen, Zheng-Hui ; Du, Yan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c230t-1a6cdabb44f81c0fbe94e1b269379bd410a1d22d344548bba317045fb810a1013</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Female</topic><topic>Humans</topic><topic>Leukemia, Myeloid, Acute - drug therapy</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Leukemia, Myeloid, Acute - mortality</topic><topic>Leukemia, Myeloid, Acute - pathology</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Necroptosis - genetics</topic><topic>Prognosis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pan, Yu-Qing</creatorcontrib><creatorcontrib>Yang, Kai</creatorcontrib><creatorcontrib>Zhang, Xi</creatorcontrib><creatorcontrib>Li, Yi-Xun</creatorcontrib><creatorcontrib>Guo, Chong</creatorcontrib><creatorcontrib>Chen, Zheng-Hui</creatorcontrib><creatorcontrib>Du, Yan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pan, Yu-Qing</au><au>Yang, Kai</au><au>Zhang, Xi</au><au>Li, Yi-Xun</au><au>Guo, Chong</au><au>Chen, Zheng-Hui</au><au>Du, Yan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Construction and validation of a necroptosis-related prognostic signature in acute myeloid leukemia</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2024-05-31</date><risdate>2024</risdate><volume>103</volume><issue>22</issue><spage>e38432</spage><pages>e38432-</pages><issn>0025-7974</issn><issn>1536-5964</issn><eissn>1536-5964</eissn><abstract>Acute myeloid leukemia (AML), an uncommonly low 5-year survival and high mortality rate, is a potentially catastrophic diagnosed subtype of leukemia. The development of new prognostic markers is urgently needed to guide its treatment. Necroptosis is a newly defined biological process for regulating cell death, and previous studies have confirmed that the abnormality of the physical function can lead to multiple malignancies. Here, we performed necroptosis-related genes (NRGs) to build a predictive model in the Cancer Genome Atlas (TCGA)-AML patients, thus exploring the correlation between the NRG prognosis signature (NRG score) of this model and immune infiltration, pathway activity, clinical features, and immunotherapy. Besides, we computed the statistical measure Spearman rank correlation between the NRG score and the Log IC50 values of therapeutic agents. Subsequently, we divided the TCGA-AML cohort into 2 groups, one with high scores and the other with low scores depending on the model score. AML patients with high NRG scores exhibited a lower estimated overall survival (OS) rate than those with low NRG scores, which was confirmed in the validation set. The prognostic value of the constructed NRG signature to the AML, independent of other variables, was demonstrated by uni- and multivariate stepwise regression analysis. When comparing the infiltrating states of specialized cells associated with immune system from the 2 groups, B cells naive, Plasma cells, and monocytes represented significant differences among various subgroups of samples. Moreover, the 30 hallmark-related pathways related to necroptosis characteristics were remarkably different between the high/low NRG score groups. And patients showed remarkable NRG score distribution in clinical features of bone marrow lymphocyte, category, and FAB classifications. Besides, we found that the BIRB0796, VX680, Vorinostat, and Axitinib positively related with NRG score, whereas CI. 1040, PD. 0325901, Z.L LNle. CHO, and AZD6244 negatively correlated with the NRG score. These drugs may provide a reference for subsequent treatment.</abstract><cop>United States</cop><pmid>39259061</pmid><doi>10.1097/MD.0000000000038432</doi><orcidid>https://orcid.org/0009-0009-6940-631</orcidid><orcidid>https://orcid.org/0009-0009-6940-631X</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-7974
ispartof Medicine (Baltimore), 2024-05, Vol.103 (22), p.e38432
issn 0025-7974
1536-5964
1536-5964
language eng
recordid cdi_proquest_miscellaneous_3102881499
source LWW Online; IngentaConnect Journals; PubMed Central
subjects Adult
Aged
Biomarkers, Tumor - genetics
Female
Humans
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - mortality
Leukemia, Myeloid, Acute - pathology
Male
Middle Aged
Necroptosis - genetics
Prognosis
title Construction and validation of a necroptosis-related prognostic signature in acute myeloid leukemia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T11%3A25%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Construction%20and%20validation%20of%20a%20necroptosis-related%20prognostic%20signature%20in%20acute%20myeloid%20leukemia&rft.jtitle=Medicine%20(Baltimore)&rft.au=Pan,%20Yu-Qing&rft.date=2024-05-31&rft.volume=103&rft.issue=22&rft.spage=e38432&rft.pages=e38432-&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000038432&rft_dat=%3Cproquest_cross%3E3102881499%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c230t-1a6cdabb44f81c0fbe94e1b269379bd410a1d22d344548bba317045fb810a1013%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3102881499&rft_id=info:pmid/39259061&rfr_iscdi=true